Direct oral anticoagulants are an alternative to anticoagulants based on vitamin K antagonists. Monitoring of direct oral anticoagulant concentration levels is necessary in specific cases (e.g. in emergency conditions, for determination of the cause of bleeding, adverse effects, risk of drug-direct oral anticoagulants interaction); therefore, a sensitive and specific method is needed. A methanol protein precipitation method followed by liquid chromatography with high-resolution mass spectrometry was developed for simultaneous separation and determination of apixaban, betrixaban, edoxaban, dabigatran, rivaroxaban and ximelagatran. The proposed method was fully validated in terms of linearity, the limits of detection and quantification, intra- and inter-day trueness and precision, recovery, matrix effect, process efficiency and stability. The method shows a strong correlation (Pearson's correlation coefficients > 0.92) with coagulation assays of apixaban, dabigatran and rivaroxaban (dilute thrombin time for gatrans and anti Xa factor (anti-Xa) activity for xabans). In addition, the developed method was applied for the identification and determination of apixaban and dabigatran in post-mortem serum samples. The developed method is a good alternative to coagulation tests which may show various interferences.

Department of Forensic Medicine and Medical Law Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc Olomouc Czech Republic

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Blaich, C., Müller, C., Michels, G., & Wiesen, M. H. J. (2015). Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 53, 1981-1990. https://doi.org/10.1515/cclm-2014-1108

Çelebier, M., Reçber, T., Koçak, E., Altinöz, S., & Kir, S. (2016). Determination of rivaroxaban in human plasma by solid-phase extraction-high performance liquid chromatography. Journal of Chromatography Science, 54, 216-220. https://doi.org/10.1093/chromsci/bmv135

Derogis, P. B. M., Sanches, L. R., de Aranda, V. F., Colombini, M. P., Mangueira, C. L. P., Katz, M., Faulhaber, A. C. L., Mendes, C. E. A., dos Santos Ferreira, C. E., França, C. N., & de Campos Guerra, J. C. (2017). Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). PLoS ONE, 12, e0171272. https://doi.org/10.1371/journal.pone.0171272

Ferrone, V., Todaro, S., Carlucci, M., Fontana, A., Ventrella, A., Carlucci, G., & Milanetti, E. (2020). Optimisation by response surface methodology of a dispersive magnetic solid phase extraction exploiting magnetic graphene nano composite coupled with UHPLC-PDA for simultaneous determination of new oral anticoagulants (NAOs) in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 179, 112992. https://doi.org/10.1016/j.jpba.2019.112992

Hanada, K., Matsumoto, S., Shibata, S., Matsubara, H., Tsukumira, Y., & Takahashi, H. (2018). A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty. Biomedical Chromatography, 32, e4213. https://doi.org/10.1002/bmc.4213

Harenberg, J., & Kreamer, R. (2012). Measurement of the new anticoagulants. Thrombosis Research, 1, S106-S113. https://doi.org/10.1016/S0049-3848(12)70028-2

Harenberg, J., Marx, S., Erdle, S., & Krämer, R. (2012). Determination of the anticoagulant effects of new oral anticoagulants: An unmet need. Expert Review of Hematology, 5, 107-113. https://doi.org/10.1586/ehm.11.79

Harenberg, J., Shanshan, D., Krämer, S., Weiss, C., Krämer, R., & Wehling, M. (2015). Patient's serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Seminars in Thrombosis and Hemostasis, 41, 228-236. https://doi.org/10.1055/s-0035-1544158

ICH. (2019). Guideline M10 on bioanalytical method validation. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf

Iqbal, M., Khalil, N. Y., Imam, F., & Anwer, K. (2015). A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. Journal of Thrombosis and Thrombolysis, 39, 79-88. https://doi.org/10.1007/s11239-014-1121-2

Jensen, K. O. F., Hansen, S. H., Goetze, J. P., Jesting, A., Stensballe, J., & Hansen, H. (2017). Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients. European Journal Heamatology, 99, 431-436. https://doi.org/10.1111/ejh.12942

Matuszewski, B. K., Constanzer, M. L., & Chavez-Eng, C. M. (2003). Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry, 75, 3019-3030. https://doi.org/10.1021/ac020361s

Mekaj, Y., Mekaj, A., Duci, S., & Miftari, E. (2015). New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and Clinical Risk Managament, 11, 967-977. https://doi.org/10.2147/TCRM.S84210

Nouman, E. G., Al-Ghobashy, M. A., & Lofty, H. M. (2015). Development and validation of LC-MS/MS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma. Journal of Chromatography B, 989, 37-45. https://doi.org/10.1016/j.jchromb.2015.02.042

Peacock, W. F., Rafique, Z., & Singer, A. J. (2016). Direct-acting oral anticoagulants: Practical considerations for emergency medicine physicians. Emergency Medicine International, 2016, 1781684. https://doi.org/10.1155/2016/1781684

Reçber, T., Haznedaroglu, I. C., & Çelebier, M. (2020). Review on characteristics and analytical methods of rivaroxaban. Critical Reviews in Analytical Chemistry, 4, 1-13. https://doi.org/10.1080/10408347.2020.1839735

Samama, M. M., & Guinet, C. (2011). Laboratory assessment of new anticoagulants. Clinical Chemistry and Laboratory Medicine, 49, 761-772. https://doi.org/10.1515/CCLM.2011.134

Schellings, M. W. M., Boonen, K., Schmitz, E. M. H., Jonkers, F., van den Heuvel, D. J., Besselaar, A., Hendriks, M. W. M., & van de Kerkhof, D. (2016). Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thrombosis Research, 139, 128-134. https://doi.org/10.1016/j.thromres.2016.01.012

Shaikh, K., Mungantiwar, A., Halde, S., & Pandita, N. (2020). Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. European Journal of Mass Spectrometry, 26, 91-105. https://doi.org/10.1177/1469066719875014

Sikorska, J., & James, U. (2017). Direct oral anticoagulants: A quick guide. European Cardiology, 12, 40-45. https://doi.org/10.15420/ecr.2017:11:2

Slavik, L., Jacova, J., Friedecky, D., Ulehlova, J., Tauber, Z., Prochazkova, J., Hlusi, A., & Palova, M. (2019). Evaluation of the DOAC-Stop procedure by LC-MS/MS assays for determining the residual activity of dabigatran, rivaroxaban, and apixaban. Clinical and Applied Thrombosis/Hemostasis, 25, 1-6. https://doi.org/10.1177/1076029619872556

Slavik, L., Lukes, J., Friedecky, D., Zhanelova, M., Nemcova, M., Ulehlova, J., Prochazkova, J., Hlusi, A., Palova, M., & Vaclavik, J. (2018). Multianalyte determination of DOACs using LC-MS/MS and comparison with functional coagulation assays. Clinical Laboratory, 64, 1611-1621. https://doi.org/10.7754/Clin.Lab.2018.180335

Tilea, I., Popa, D. S., Xantus, T. S., Primejdie, D., Grigorescu, B., Tilea, B., Bocicor, A. E., & Varga, A. (2015). Determination of apixaban levels in human plasma by a high-throughput liquid chromatography tandem mass spectrometry assay. Revista Romana de Medicina de Laborator, 23, 115-125. https://doi.org/10.1515/rrlm-2015-0006

Zhang, M., Moore, G. A., & Chin, P. K. (2020). Simultaneous determination of dabigatran, rivaroxaban, and Apixaban in human plasma by liquid chromatography/tandem mass spectrometry. Therapeutic Drug Monitoring, 42, 473-480. https://doi.org/10.1097/FTD.0000000000000744